Sigachi Industries Limited — Investor Meet, 19-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Sigachi Industries reported a robust performance for Q2 FY25, with operating income rising by 25.91% YoY to INR 124.9 Cr. EBITDA grew significantly, increasing by 36.91% YoY to INR 29 Cr, leading to a margin of 21.38%. Net profit surged 39.09% YoY to INR 21 Cr, with a PAT margin of 16.81%. The revenue from the Microcrystalline Cellulose (MCC) segment increased 15.35% YoY, while the Operations and Maintenance (O&M) segment grew 21.08% in Q2 FY25.

**Future Outlook and Growth Drivers:** Management indicated a strategic focus on high-margin regulated markets, especially in the API segment, aiming for nine CEP approvals within the year. With the integration of the API unit acquired last year, they plan to expand capacity from 100 KL to 250 KL over the next year. They have also entered the pharmaceutical coatings market with products like PureCoat and UltraMod, intending to enhance drug bioavailability.

**Order Book and Operational Updates:** The company is progressing with an 1,800 metric tons per annum CCS facility in Dahej, set for FY26 commercial launch. They operate in 65 countries, and strategic partnerships in the MENA region are expected to bolster their market presence further.

**Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Analysts raised concerns about gross margin contraction due to pricing strategies aimed at market penetration, with management reconfirming that margins should improve post-expansion.

- **Market Position and Competitive Landscape:** There was a discussion regarding market share gains attributed to the diverse product lines and competitive pricing strategies.

- **Operational Challenges or Risks:** Analysts questioned supply chain challenges and their impact on margins, to which management expressed confidence in recovery as market share is secured.

- **Capex and Capital Allocation:** A deliberate approach to raising USD 100 million via foreign currency convertible bonds was discussed, with funds earmarked for strategic land acquisitions to support expansion plans.

- **Strategic Priorities and Long-Term Vision:** Emphasizing commitment to innovation and sustainable growth, the management outlined long-term strategies to increase operational efficiencies and maximize stakeholder value.

**Market or Regulatory Updates:** Regulatory clarity around foreign markets remains crucial, with an eye on new policies potentially benefiting the Indian pharma segment.

**Strategic Focus Areas:** The company maintains a strong emphasis on innovation, operational expansion, and strategic partnerships, reinforcing their competitive position in both domestic and international markets.

**Investor Insight:** The observed financial performance, combined with strategic growth initiatives, suggests a favorable outlook for investors, aligning with a potential 'buy' position, particularly as they navigate upcoming regulatory approvals and expand their API segment. The management’s focus on achieving economies of scale and enhancing operational efficiencies is a promising sign for sustained growth.